About entrinsic bioscience
entrinsic bioscience is a Healthcare company based in Norwood (United States) founded in 2012. It operates as a drugs for tumors, cystic fibrosis, and hemochromatosis are developed. entrinsic bioscience has raised $19.2 million across 5 funding rounds from investors including Johnson & Johnson Innovation. entrinsic bioscience offers products and services including Biomapping Platform and Functional Amino Acids. Its focus areas include Life Sciences, Oncology, Drugs and Brain Cancer. Its competitors include Imvax, GT Medical Technologies, Basilea, Laminar Pharma and SOM Biotech and 3 more; 6 of its 8 listed competitors have raised funding.
Company details
Entrinsic Bioscience was founded in 2012 and is based in Norwood, United States. Operations center on biotechnology, with drugs developed for tumors, cystic fibrosis, and hemochromatosis. The RxAA platform is employed to produce therapeutic candidates. Increases in chloride secretion have been observed in pre-clinical in vitro studies for one candidate. Reductions in diarrhea and associated symptoms from NET and carcinoid syndrome cancers were noted in clinical trials.
- Headquarters Norwood, United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website entrinsicbioscience.com
- Social LinkedIn
- Total Equity Funding$19.2M (USD)
in 5 rounds
- Latest Funding Round$49M (USD), Debt – Conventional
Jun 2021
- Investors
Products & Services of entrinsic bioscience
entrinsic bioscience offers a comprehensive portfolio of products and services, including Biomapping Platform and Functional Amino Acids.
Identifies amino acid combinations for health benefits.
Patented combinations for targeted health applications.
Funding Insights of entrinsic bioscience
entrinsic bioscience has successfully raised a total of $19.2M across 5 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $49 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $19.2M
- Total Rounds 5
- Last Round Debt – Conventional — $49M
- First Round $7.5M
(Mar 2016)
- Investors Count 1
All 5 funding rounds of entrinsic bioscience with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2021 | $49M | Debt – Conventional | – | – | |
| Jun 2018 | $1.7M | Series A | – | – | – |
| Jan 2018 | $3M | Series A | – | – | – |
| Feb 2017 | $7M | Series A | – | – | – |
| Mar 2016 | $7.5M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in entrinsic bioscience
entrinsic bioscience has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Johnson & Johnson Innovation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | jnjinnovation.com | - |
Investor details for entrinsic bioscience
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of entrinsic bioscience
3 dated milestones of entrinsic bioscience across 9 years, from founding to its latest funding, stage changes and deals.
- Founded entrinsic bioscience is founded.
- Funding First funding round of $7.5M.
- Funding Latest funding round, Debt – Conventional, of $49.0M.
Competitors of entrinsic bioscience
entrinsic bioscience has 8 listed competitors in our database, 6 of them funded. They include Imvax, GT Medical Technologies, Basilea, Laminar Pharma and SOM Biotech, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| imvax.com | 2015 | Philadelphia, United States | $203.83M | 50 | Patient-specific cell vaccines for glioma treatment are developed. | |
| gtmedtech.com | 2017 | Tempe, United States | $129.94M | 29 | Medical devices for brain tumor radiation therapy are provided. | |
| basilea.com | 1999 | Basel, Switzerland | – | – | Antibiotics, antifungals, and oncology drugs are developed for disease treatment. | |
| laminarpharma.com | 2006 | Palma, Spain | $14.71M | – | Melipathy-based drugs are developed for cancer, Alzheimer's, and inflammation treatments. | |
| sombiotech.com | 2009 | Barcelona, Spain | $28.52M | – | Developer of platform for screening compounds to treat rare diseases | |
| curativebiotech.com | 1995 | Boca Raton, United States | – | – | Therapeutic drugs for cancer, eye, and infectious diseases are developed. | |
| laevoroc.com | 2019 | Hunenberg, Switzerland | $1.1M | – | Therapeutics for pancreatic, ovarian, breast, and brain cancers are developed. | |
| glionova.com | 2014 | Stockholm, Sweden | $5.7M | – | Develops innovative technologies for novel therapies targeting glioblastoma. |
Detailed competitors of entrinsic bioscience
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
10 companies that operate in the same segment as entrinsic bioscience (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Entrinsic Bioscience
Complete news archive for entrinsic bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about entrinsic bioscience
entrinsic bioscience was founded in 2012 and raised its 1st funding round 4 years after it was founded.
entrinsic bioscience is headquartered in Norwood, United States. It is registered at Norwood, Massachusetts, United States.
entrinsic bioscience is a funded company, having raised a total of $19.2M across 5 funding rounds to date. The company's 1st funding round was a Series A of $7.5M, raised on Mar 2016.
Entrinsic Bioscience was founded in 2012 and is based in Norwood, United States. Operations center on biotechnology, with drugs developed for tumors, cystic fibrosis, and hemochromatosis. The RxAA platform is employed to produce therapeutic candidates. Increases in chloride secretion have been observed in pre-clinical in vitro studies for one candidate. Reductions in diarrhea and associated symptoms from NET and carcinoid syndrome cancers were noted in clinical trials.
entrinsic bioscience's top competitors include Imvax, GT Medical Technologies and Basilea.
entrinsic bioscience offers Biomapping Platform and Functional Amino Acids.
entrinsic bioscience has 1 investor. Key investors include Johnson & Johnson Innovation.